Dimitrios Pantelis1,2, Robert Hüneburg3,4, Ronja Adam3,5, Stefanie Holzapfel3,5, Heidrun Gevensleben3,6, Jacob Nattermann3,4, Christian P Strassburg3,4, Stefan Aretz3,5, Jörg C Kalff7,3. 1. Department of General, Visceral, Thoracic and Vascular Surgery, University Hospital of Bonn, Bonn, Germany. dimitrios.pantelis@ukb.uni-bonn.de. 2. Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany. dimitrios.pantelis@ukb.uni-bonn.de. 3. Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany. 4. Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany. 5. Institute of Human Genetics, University Hospital Bonn, Bonn, Germany. 6. Institute of Pathology, University Hospital Bonn, Bonn, Germany. 7. Department of General, Visceral, Thoracic and Vascular Surgery, University Hospital of Bonn, Bonn, Germany.
Abstract
PURPOSE: Germline mutations in several genes confer a relevant lifetime risk of gastric cancer. In this context, an increasing involvement of a surgeon can be seen, mainly with the question of performing a prophylactic operation. METHODS: Patients with hereditary tumor syndromes predisposing for gastric cancer who received care leading to prophylactic total gastrectomy in our Center for Hereditary Tumor Syndromes were analyzed. For each patient, the multidisciplinary decision-making process, the perioperative course, and the histopathologic findings were assessed. Short-term morbidity was evaluated based on the medical reports. RESULTS: The analysis includes nine patients (six female, three male) with a median age of 41.6 (range 23-60) years. Indication for prophylactic total gastrectomy was based on family history and genetic analysis (eight patients with a germline mutation of the CDH1 gene and one patient with a SMAD4 mutation). Removal of the entire gastric mucosa was documented intraoperatively by fresh frozen section examination. Extended (DII) lymphadenectomy was performed in four patients. Histopathologic examination of gastrectomy specimens revealed six patients (6/9, 67 %) with multifocal signet ring cell carcinomas. In our series, prophylactic total gastrectomy was a safe procedure without mortality and low morbidity. CONCLUSIONS: Patients with hereditary syndromes predisposing for gastric cancer should be evaluated for this curative procedure in a specialized center. Further research is necessary, and the implementation of nationwide registers including patients with prophylactic gastrointestinal operations due to hereditary tumor syndrome is advisable.
PURPOSE: Germline mutations in several genes confer a relevant lifetime risk of gastric cancer. In this context, an increasing involvement of a surgeon can be seen, mainly with the question of performing a prophylactic operation. METHODS:Patients with hereditary tumor syndromes predisposing for gastric cancer who received care leading to prophylactic total gastrectomy in our Center for Hereditary Tumor Syndromes were analyzed. For each patient, the multidisciplinary decision-making process, the perioperative course, and the histopathologic findings were assessed. Short-term morbidity was evaluated based on the medical reports. RESULTS: The analysis includes nine patients (six female, three male) with a median age of 41.6 (range 23-60) years. Indication for prophylactic total gastrectomy was based on family history and genetic analysis (eight patients with a germline mutation of the CDH1 gene and one patient with a SMAD4 mutation). Removal of the entire gastric mucosa was documented intraoperatively by fresh frozen section examination. Extended (DII) lymphadenectomy was performed in four patients. Histopathologic examination of gastrectomy specimens revealed six patients (6/9, 67 %) with multifocal signet ring cell carcinomas. In our series, prophylactic total gastrectomy was a safe procedure without mortality and low morbidity. CONCLUSIONS:Patients with hereditary syndromes predisposing for gastric cancer should be evaluated for this curative procedure in a specialized center. Further research is necessary, and the implementation of nationwide registers including patients with prophylactic gastrointestinal operations due to hereditary tumor syndrome is advisable.
Authors: Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt Journal: Am J Gastroenterol Date: 2015-02-03 Impact factor: 10.864
Authors: Margaret O'Malley; Lisa LaGuardia; Matthew F Kalady; Joseph Parambil; Brandie Heald; Charis Eng; James Church; Carol A Burke Journal: Dis Colon Rectum Date: 2012-08 Impact factor: 4.585
Authors: J J Bonenkamp; J Hermans; M Sasako; C J van de Velde; K Welvaart; I Songun; S Meyer; J T Plukker; P Van Elk; H Obertop; D J Gouma; J J van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus Journal: N Engl J Med Date: 1999-03-25 Impact factor: 91.245
Authors: P Guilford; J Hopkins; J Harraway; M McLeod; N McLeod; P Harawira; H Taite; R Scoular; A Miller; A E Reeve Journal: Nature Date: 1998-03-26 Impact factor: 49.962
Authors: K Woodford-Richens; S Bevan; M Churchman; B Dowling; D Jones; C G Norbury; S V Hodgson; D Desai; K Neale; R K Phillips; J Young; B Leggett; M Dunlop; P Rozen; C Eng; D Markie; M A Rodriguez-Bigas; E Sheridan; T Iwama; D Eccles; G T Smith; J C Kim; K M Kim; J R Sampson; G Evans; S Tejpar; W F Bodmer; I P Tomlinson; R S Houlston Journal: Gut Date: 2000-05 Impact factor: 23.059
Authors: P C Hebbard; A Macmillan; D Huntsman; P Kaurah; F Carneiro; X Wen; A Kwan; D Boone; F Bursey; J Green; B Fernandez; D Fontaine; D A Wirtzfeld Journal: Ann Surg Oncol Date: 2009-05-01 Impact factor: 5.344
Authors: Matthew G K Benesch; Stuart R Bursey; Andrew C O'Connell; Morag G Ryan; Carrie L Howard; Cecily C Stockley; Alexander Mathieson Journal: Cancers (Basel) Date: 2021-05-26 Impact factor: 6.639